Archive 1995–2023
2009, volume 25, issue 2
Original article
Polish patients of EUFESTS after 12 months antipsychotic treatment: risk of drug discontinuation and parameters of metabolic syndrome
Jolanta Rabe-Jabłońska, Tomasz Pawełczyk, Jerzy Samochowiec, Marcin Olajossy, Janusz Rybakowski
Farmakoterapia w Psychiatrii i Neurologii, 2009, 2, 75–83
Original article
Polish patients with I episode of schizophrenia in EUFEST study: change of the psychopatology level depending on the antipsychotic medication used
Marcin Olajossy, Marek Masiak, Jerzy Samochowiec, Jolanta Rabe-Jabłońska, Janusz Rybakowski
Farmakoterapia w Psychiatrii i Neurologii, 2009, 2, 85–93
Original article
Clinical improvement and metabolic effects of antipsychotic drugs in schizophrenia
Katarzyna Olszewska, Janusz Rybakowski
Farmakoterapia w Psychiatrii i Neurologii, 2009, 2, 95–100
Review article
Selective agonist of the hypothalamic melanocortin receptors; bremelanotide as a new drug in pharmacotherapy of sexual dysfunctions
Artur Pałasz, Marek Krzystanek, Irena Krupka-Matuszczyk, Marcin Kamiński, Ryszard Wiaderkiewicz
Farmakoterapia w Psychiatrii i Neurologii, 2009, 2, 101–108
Case report
A case of catatonic schizophrenia – successful outcome of treatment with aripiprazole and clozapine
Miłosz Krzywotulski, Paweł Wójciak, Janusz Rybakowski
Farmakoterapia w Psychiatrii i Neurologii, 2009, 2, 109–112
Scientific conference report
Sprawozdanie z seminarium naukowego ECNP-EPA w Czerniejewie, 28-30 maja 2009 roku
Jan Jaracz, Agnieszka Remlinger-Molenda
Farmakoterapia w Psychiatrii i Neurologii, 2009, 2, 113–115